DAIICHI SANKYO, INC.
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 48
- Registration Number
- NCT01956305
- Locations
- πΊπΈ
Worldwide Clinical Trials, San Antonio, Texas, United States
A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 107
- Registration Number
- NCT01877382
- Locations
- πΊπΈ
Karmanos Cancer Institute, Detroit, Michigan, United States
πΊπΈColumbia University College of Physicians and Surgeons, New York, New York, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2013-05-27
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 52
- Registration Number
- NCT01862939
- Locations
- πΊπΈ
Celerion, Tempe, Arizona, United States
A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma
Phase 1
Terminated
- Conditions
- V600-mutated BRAF Unresectable MelanomaV600-mutated BRAF Metastatic MelanomaStage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor
- Interventions
- First Posted Date
- 2013-04-08
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 13
- Registration Number
- NCT01826448
- Locations
- πΊπΈ
UCLA, Los Angeles, California, United States
πΊπΈUniversity of Colorado, Denver, Aurora, Colorado, United States
πΊπΈVanderbilt University, Nashville, Tennessee, United States
Edoxaban in Peripheral Arterial Disease
Phase 2
Completed
- Conditions
- Peripheral Arterial Disease
- Interventions
- First Posted Date
- 2013-03-01
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 203
- Registration Number
- NCT01802775
- Locations
- π§πͺ
Edgem, Edegem, Belgium
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
Phase 1
Completed
- Conditions
- Patients With Newly Diagnosed Glioblastoma
- Interventions
- First Posted Date
- 2013-02-13
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 65
- Registration Number
- NCT01790503
- Locations
- πΊπΈ
Northwestern Memorial Hospital, Chicago, Illinois, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis
Phase 2
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: 20 mg ASB17061Drug: PlaceboDrug: 10 mg ASB17061Drug: 5 mg ASB17061
- First Posted Date
- 2012-12-28
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 370
- Registration Number
- NCT01756898
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 383
- Registration Number
- NCT01755767
Effect of Tivantinib on the QTC Interval in Cancer Subjects
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 38
- Registration Number
- NCT01699061
- Locations
- πΊπΈ
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Phase 2
Completed
- Conditions
- Venous ThrombosisDeep Vein Thrombosis
- Interventions
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 85
- Registration Number
- NCT01662908